Leif Stenke

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

Stephen H. Petersdorf, Kenneth J. Kopecky, Marilyn L. Slovak et al. · Blood · 2013 · 621 citations · Full text

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Johan Richter, Joëlle Guilhot, Franz Gruber et al. · The Lancet Oncology · 2018 · 587 citations · Full text

Hematological Malignancy, Medicine, Chronic Myeloid Leukaemia +10

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

Hagop M. Kantarjian, Andreas Hochhaus, Giuseppe Saglio et al. · The Lancet Oncology · 2011 · 511 citations

Chronic Phase, Hematological Malignancy, Nilotinib Versus Imatinib +10

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

Matthew S. Zabriskie, Christopher A. Eide, Srinivas K. Tantravahi et al. · Cancer Cell · 2014 · 363 citations · Full text

Hematological Malignancy, Ph Chromosome-positive Leukemia, Genetics +7

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

Satu Mustjoki, Marja Ekblom, T. Petteri Arstila et al. · Leukemia · 2009 · 316 citations

Medicine, Malignant Blood Disorder, Immunology +5